Cell Division

Cell Division is an open-access peer-reviewed online journal published by BioMed Central, part of Springer Nature, founded in 2006 and devoted to the molecular control of the cell cycle and its links to cancer, with a 2025 Journal Impact Factor of 4.9《细胞分裂》是开放获取的同行评审在线期刊，由（Springer Nature）旗下的（BioMed Central）出版，2006 年创刊，专注细胞周期的分子调控及其与癌症的联系，2025 年影响因子为 4.9。

Scope

• The journal covers all molecular aspects of cell cycle control and cancer, from cell growth and proliferation to survival and differentiation期刊涵盖细胞周期调控与癌症的全部分子层面，从细胞生长、增殖到存活与分化。
• Signalling, gene transcription and protein synthesis are central topics, reflecting its focus on regulatory mechanisms信号传导、基因转录与蛋白质合成是核心主题，体现其对调控机制的关注。
• Genome integrity, chromosome stability and centrosome duplication are covered in depth基因组完整性、染色体稳定性与中心体复制得到深入覆盖。
• DNA replication, DNA damage and DNA repair form a further major strand（DNA）复制、（DNA）损伤与（DNA）修复构成另一主要方向。
• Mitosis, the spindle assembly checkpoint, ubiquitin-mediated degradation, apoptosis and cell death are within scope有丝分裂、纺锤体组装检查点、泛素介导的降解、细胞凋亡与细胞死亡均在收稿范围之内。
• Cell fate decisions and the interplay between cell cycle regulation, development and cancer models are explicitly welcomed细胞命运决定，以及细胞周期调控、发育与癌症模型之间的相互作用，明确受到欢迎。
• The journal publishes research articles, reviews and commentaries, and it also runs thematic collections on cancer biomarkers and related topics期刊发表研究论文、综述与评论，并组织关于癌症生物标志物及相关主题的专题文集。

History

• Cell Division was founded in 2006 by BioMed Central, and its launch editorial by Philipp Kaldis and Michele Pagano appeared on 3 April 2006《细胞分裂》由（BioMed Central）于 2006 年创办，由（Philipp Kaldis）与（Michele Pagano）撰写的创刊社论于 2006 年 4 月 3 日发表。^[1]
• Kaldis, then at the National Cancer Institute, and Pagano presented it as an open-access forum for the cell cycle community当时任职于（National Cancer Institute）的（Kaldis）与（Pagano），将其定位为服务细胞周期学界的开放获取论坛。
• It has been online-only since launch, with the electronic ISSN 1747-1028 and the DOI prefix 10.1186该刊自创刊起即为纯在线出版，电子刊号为 1747-1028，（DOI）前缀为 10.1186。
• It publishes continuously, with one volume per year and articles identified by article numbers期刊采用连续出版模式，每年一卷，文章以文章编号标识。
• The journal celebrated its twentieth anniversary in 2026 with a retrospective collection of its most highly cited papers from 2006 to 20262026 年，期刊迎来二十周年，并推出 2006 至 2026 年高被引论文回顾文集。
• The 2025 Journal Impact Factor is 4.9, against 2.2 in 2024, 2.826 in 2022 and 5.13 in 20212025 年影响因子为 4.9，2024 年为 2.2，2022 年为 2.826，2021 年为 5.13。
• It is indexed in Science Citation Index Expanded, Scopus, PubMed Central, DOAJ and EMBASE该刊被（Science Citation Index Expanded）、（Scopus）、（PubMed Central）、（DOAJ）与（EMBASE）收录。

Editors

• The Editor-in-Chief is Jiri Kohoutek of Masaryk University in Brno, Czechia, whose specialisms include transcription, cyclin-dependent kinases and RNA splicing现任主编为捷克布尔诺（Masaryk University）的（Jiri Kohoutek），其专长包括转录、周期蛋白依赖性激酶与（RNA）剪接。
• Ten associate editors serve the journal, among them Chun-Chia Cheng, Douglas Cress, Dawit Kidane and Domenico Maiorano期刊设有 10 位副编辑，其中包括（Chun-Chia Cheng）、（Douglas Cress）、（Dawit Kidane）与（Domenico Maiorano）。
• The editorial board has 22 members from the United States, the United Kingdom, France, China, Japan, Canada, Israel, Italy, Thailand and Czechia编委会由 22 位成员组成，来自美国、英国、法国、中国、日本、加拿大、以色列、意大利、泰国与捷克。
• Cell Division operates single-anonymous peer review, in which reviewers know the authors but their reports are anonymized《细胞分裂》实行单盲评审，审稿人知晓作者身份，但其评审报告对作者匿名。
• The median time from submission to first decision is 13 days, and the journal recorded 284.8 thousand downloads in 2025从投稿到首次决定的中位时间为 13 天，2025 年下载量达 28.48 万次。
• The journal is recruiting associate editors and commissions thematic collections on solid and haematological malignancies期刊正在招募副编辑，并就实体瘤与血液系统恶性肿瘤组织专题文集。